04th week of 2014 patent applcation highlights part 45 |
Patent application number | Title | Published |
20140024555 | METHOD OF IDENTIFYING SOLUBLE PROTEINS AND SOLUBLE PROTEIN COMPLEXES - Provided herein are methods of identifying a protein as soluble, as well as methods of identifying a soluble protein complex of at least two proteins. The methods allow for the determination of in vitro solubility, or both in vitro and in vivo solubility, of a protein or protein complex. | 2014-01-23 |
20140024556 | CO-COUPLING TO CONTROL REACTIVITY OF REAGENTS IN IMMUNOASSAYS - Methods and compositions for controlling immunoassay reactivity are provided. In one embodiment, a method for preparing a substrate for an immunoassay is provided in which a composition containing a reagent and a neutral material is applied to a substrate under conditions suitable to couple the reagent and the neutral material to the substrate. | 2014-01-23 |
20140024557 | METHODS OF DIAGNOSING ENDOMETRIOSIS - The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis. | 2014-01-23 |
20140024558 | Method of Treatment - The present invention relates to methods for treatment or prevention of autoimmune and inflammatory diseases and conditions by inhibiting or modifying histone demethylation. In a further aspect the invention relates to a method for identifying agents useful in said methods of treatment. The invention particularly describes the role of certain histone demethylase enzymes in these diseases and conditions and their use as therapeutic and screening targets. | 2014-01-23 |
20140024559 | Optical Lens System and Method for Microfluidic Devices - An apparatus for imaging one or more selected fluorescence indications from a microfluidic device. The apparatus includes an imaging path coupled to least one chamber in at least one microfluidic device. The imaging path provides for transmission of one or more fluorescent emission signals derived from one or more samples in the at least one chamber of the at least one microfluidic device. The chamber has a chamber size, the chamber size being characterized by an actual spatial dimension normal to the imaging path. The apparatus also includes an optical lens system coupled to the imaging path. The optical lens system is adapted to transmit the one or more fluorescent signals associated with the chamber. | 2014-01-23 |
20140024560 | DRILLING FLUID USING SURFACTANT PACKAGE - A drilling fluid, comprising an aqueous continuous phase, and a surfactant system comprising a mixture of an ester phosphate and a non-ionic ethoxylated alcohol. The drilling fluid may also contain one or more of at least one salt, an alkaline material, a viscosifying agent, a starch or starch derivative, a bridging agent, a weighting material, and a diesel oil or non-aromatic oil. | 2014-01-23 |
20140024561 | Absorbent Polymers, and Related Methods of Making and Using the Same - Compositions used in subterranean operations include absorbent polymers useful in controlling fluids within a subterranean formation; a method includes the steps of providing a treatment fluid having an absorbent polymer, the absorbent polymer including an aminoalcohol or polyamine-modified water-soluble polymer which includes a carboxylic acid derivative group, the method further includes placing the treatment fluid in at least a portion of a subterranean formation. | 2014-01-23 |
20140024562 | HIGH SOLIDS CONTENT SLURRIES, SYSTEMS AND METHODS - High solids content slurry, systems and methods. The slurry comprises a carrier fluid and a solids mixture of first, second, third and fourth particle size distribution (PSD) modes wherein the first PSD mode is at least three times larger than the second PSD mode, which is larger than the third PSD mode, which is larger than the fourth PSD mode, and wherein at least one of the second and third PSD modes is less than 3 times larger than the respective third or fourth PSD mode. The method comprises forming the slurry, positioning a screen in a wellbore and circulating the slurry through the wellbore such that the solids mixture is deposited between the screen and the wellbore. The system comprises a pump to circulate the slurry, a workstring to position the screen and means for converting the slurry to a gravel pack. | 2014-01-23 |
20140024563 | ANTI-WEAR COATINGS FOR COMPRESSOR WEAR SURFACES - Anti-wear surface coatings and methods for making them are provided. Such anti-wear surface coatings are particularly suitable for use in a compressor, such as a scroll or rotary compressor. A precursor powder material can be applied via spraying to a wear surface of a metal component of the scroll or rotary compressor. The precursor powder material comprises a powderized thermoplastic polymer (e.g., PEEK), a first lubricant particle (e.g., molybdenum disulfide (MoS | 2014-01-23 |
20140024564 | Spherical Copper/Molybdenum Disulfide Powders, Metal Articles, and Methods for Producing Same - A method of producing a compacted article according to one embodiment may involve the steps of: Providing a copper/molybdenum disulfide composite powder including a substantially homogeneous dispersion of copper and molybdenum disulfide sub-particles that are fused together to form individual particles of the copper/molybdenum disulfide composite powder; and compressing the copper/molybdenum disulfide composite powder under sufficient pressure to cause the copper/molybdenum disulfide composite powder to behave as a nearly solid mass. | 2014-01-23 |
20140024565 | Nanoparticle Compositions and Methods for Making and Using the Same - A composition that includes solid lubricant nanoparticles and an organic medium is disclosed. Also disclosed are nanoparticles that include layered materials. A method of producing a nanoparticle by milling layered materials is provided. Also disclosed is a method of making a lubricant, the method including milling layered materials to form nanoparticles and incorporating the nanoparticles into a base to form a lubricant. | 2014-01-23 |
20140024566 | FASTENER TIP COATING - An ease of drive coating for a fastener is formulated from a resin having at least two different friction reducing components, such as silicone and graphite. A fastener and fastener strip include a resin formulation with at last two different friction reducing components. | 2014-01-23 |
20140024567 | VISCOSITY IMPROVER GRAFTED WITH UNSATURATED ACYLATING AGENT AND AN ARYLOXYALYLKENE MONOAMINE - Disclosed is an oil-soluble lubricating oil additive composition, suitable for use as a dispersant viscosity index improver in lubricating oils; prepared by the process which comprises reacting a hydrocarbon polymer having a number average molecular weight (M | 2014-01-23 |
20140024568 | SYNERGISTIC MIXTURE - A synergistic mixture comprising from 1 to 99.9% by weight of compounds having structural elements (I) | 2014-01-23 |
20140024569 | Lubricating Oil Compositions Containing Sterically Hindered Amines as Ashless TBN Sourcces - Hindered amines useful as ashless TBN sources for lubricating oil compositions that are compatible with fluoroelastomeric engine seal materials, and lubricating oil compositions containing such compounds. | 2014-01-23 |
20140024570 | DETERGENTS OR CLEANING AGENTS CONTAINING MODIFIED ODORANTS - Washing or cleaning agents are described which contain reaction products of odorants with metal oxides, such as for example ZnO, ZrO | 2014-01-23 |
20140024571 | Granulated Foam Control Composition - A granulated foam control composition comprises a foam control agent based on a polydiorganosiloxane fluid, an organic additive of melting point 45″1 | 2014-01-23 |
20140024572 | HARD SURFACE CLEANING COMPOSITION FOR PERSONAL CONTACT AREAS - A hard surface cleaning solution having improved cleaning and descaling properties. In an embodiment, the cleaning solution comprises an organic acid, a surfactant, a solvent and a diluent. The organic acid is a carboxylic acid, preferably lactic acid, while the surfactant is selected from the group consisting amine oxides, and the solvent is an alkoxylated alcohol, preferably selected from the propylene glycol ether class of compounds. The cleaning solutions may also include other components such as colorants, fragrance enhancers, corrosion inhibitors, nonionic surfactants or other additives. | 2014-01-23 |
20140024573 | TRANSPARENT SOAP COMPRISING FLUORESCER - It has been found that transparency and water-white appearance of soap bars is improved by adding a fluorescer at selective levels. Disclosed is a transparent soap bar comprising: (i) 20 to 78 wt % total fatty matter; and (ii) 0.003 to 0.5 wt % fluorescer, wherein (i) CIELAB b* value of said bar at 0° viewing and 75° illumination is less than 0; and (ii) color of said bar expressed as Y+5R on LOVIBOND® scale is 0 to 3 and wherein the soap bar includes 0.05 to 10 wt % C2 to C3 alcohol. Also disclosed is a process for making transparent soap bar comprising the steps of: (i) saponification of oils or fatty acids in presence of polyols to get a molten mass, where after complete neutralisation, the free alkali content measured as sodium hydroxide is not greater than 0.1%; and (ii) molding said molten mass to get the bar, wherein 0.003 to 0.5 parts fluorescer and 0.05 to 10 parts C2 to C3 alcohol is mixed with said molten mass. | 2014-01-23 |
20140024574 | WATER-SOLUBLE POUCH COATED WITH A COMPOSITION COMPRISING SILICA FLOW AID - Water-soluble pouches comprise water-soluble films coated by a composition. The composition comprises silica flow aid and an absorbent material selected from the group consisting of zeolite; over-dried zeolite; talc; starch; zinc stearate; calcium stearate; micronized calcium carbonate; sodium carbonate; micronized sodium sulphate; and combinations thereof. | 2014-01-23 |
20140024575 | COMPOSITIONS COMPRISING 3,3,3-TRIFLUOROPROPENE AND AMMONIA - A composition based on 3,3,3-trifluoropropene and ammonia, and to the use thereof, especially as a heat transfer fluid. A heat-transfer composition including the composition based on 3,3,3-trifluoropropene and ammonia and also one or more additives chosen from lubricants, stabilizers, surfactants, tracers, fluorescers, odorant agents and solubilizers, and mixtures thereof. A process for heating or cooling a fluid or a body by means of a vapor compression circuit containing a heat-transfer fluid, said process successively including evaporation of the heat-transfer fluid, compression of the heat-transfer fluid, condensation of the heat fluid and depressurization of the heat-transfer fluid, in which the heat-transfer fluid is a composition based on 3,3,3-trifluoropropene and ammonia. | 2014-01-23 |
20140024576 | HEPTOSE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS - Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence. | 2014-01-23 |
20140024577 | METHODS FOR PREPARING PURIFIED LIPOPEPTIDES - The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions. | 2014-01-23 |
20140024578 | AUREOBASIDIN DERIVATIVES AND METHODS OF SYNTHESIS - In general, the invention relates to methods of synthesizing AbA derivatives that are useful for treating infection and amenable to further chemical elaboration. These novel methods are scalable for industrial production and employ safer, simpler, and more efficient process conditions. Furthermore, the invention also provides novel compounds and intermediates useful for implementing the methods described herein and/or for the treatment of infection. | 2014-01-23 |
20140024579 | METHODS FOR TREATING HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 2014-01-23 |
20140024580 | HIGH ENERGY LIQUID ENTERAL NUTRITIONAL COMPOSITION - High energy and high protein liquid nutrition enteral compositions are provided that contain micellar casein and caseinate, an optionally a small amount of whey. | 2014-01-23 |
20140024581 | PRE-THICKENED COMPACT LIQUID NUTRITIONAL COMPOSITION FOR DYSPHAGIA PATIENTS - The invention pertains to a liquid enteral nutritional composition with an energy density between 1.0 and 4.0 kcal/ml, a viscosity between 150 and 1800 mPas measured at a shear rate of 50/second at 20° C., comprising digestible carbohydrates and fat, wherein the composition further comprises at least one of (a1)) between 8-20 g protein per 100 ml of the composition, where micellar casein comprises at least 50 wt % of the total protein content of the composition, or (a2) between 16-45 en % protein, where micellar casein comprises at least 50% of the protein caloric content; and (b) anionic fibers capable of sequestering of calcium, and (c) carrageenan between 0.015 and 0.25 g per 100 ml of the composition, and its use for preventing/treating dysphagia, and/or treating/preventing malnourishment or undernourishment associated with dysphagia. | 2014-01-23 |
20140024582 | STABLE INSULIN FORMULATIONS AND METHODS OF MAKING AND USING THEREOF - The invention provides methods for improving the physical and chemical stabilities of therapeutic proteins in solutions by reducing or eliminating protein degradation, aggregation and precipitation using small molecule stabilizing agents such as proline, arginine and/or compounds capable of forming a Schiff bond with amino groups of the protein. The invention further provides liquid formulations of a monomeric insulin stabilized by one of more stabilizing agents such as proline, arginine and/or acetone. Also provided are methods of making and using the stabilized monomeric insulin formulations. | 2014-01-23 |
20140024583 | ORGANIC COMPOUNDS - The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. | 2014-01-23 |
20140024584 | TETRASUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF - The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. | 2014-01-23 |
20140024585 | Composition for the therapy of diabetes mellitus and adiposity - A composition containing at least two of the following active substances A, B, C, wherein:
| 2014-01-23 |
20140024586 | USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY - The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP- | 2014-01-23 |
20140024587 | COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS - A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. | 2014-01-23 |
20140024588 | METHOD FOR INDUCING SUSTAINED IMMUNE RESPONSE - A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response. | 2014-01-23 |
20140024589 | Follicle Stimulating Hormone Superagonists - Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders. | 2014-01-23 |
20140024590 | KRAS-Variant And Endometriosis - The invention provides methods for predicting an increased risk or probability of developing endometriosis in a patient based upon the patient's KRAS variant status. | 2014-01-23 |
20140024591 | Methods For Characterizing And Isolating Circulating Tumor Cell Subpopulations - Provided are methods and assays for cancer cell classification, cancer prognosis and treatment based on the isolation of circulating tumor cells and the characterization of their nuclear organization and telomere signatures. | 2014-01-23 |
20140024592 | Modified Relaxin Polypeptides - The present invention relates to biologically active relaxin polypeptides comprising a relaxin A chain and a B chain derived from a relaxin superfamily member, wherein the A chain comprises no intra-chain disulphide bonds. In particular embodiments the modified polypeptides comprise relaxin-3 derived A and B chains, and truncations of the A and/or B chains from the N-termini and/or C-termini. In particular embodiments the polypeptides of the invention are selective agonists or antagonists of the RXFP3 receptor. | 2014-01-23 |
20140024593 | Treatments of Gastrointestinal Disorders - The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms. | 2014-01-23 |
20140024594 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIAC ISCHEMIC INJURY - Disclosed herein are compositions and methods for the treatment and/or prevention of pathological conditions associated with ischemia/reperfusion injury and/or hypoxic injury of myocardial cell or tissue. | 2014-01-23 |
20140024595 | PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair. | 2014-01-23 |
20140024596 | DISEASE INHIBITING AGENT - At least one peptide molecule selected from EGDGHLGKPGROGE (SEQ ID NO:1), EKDGHPGKPGROGE (SEQ ID NO:2), G(POG) | 2014-01-23 |
20140024597 | INTRANASAL DELIVERY OF CELL PERMEANT THERAPEUTICS - The present invention relates to compositions and methods for the inhibition of apoptosis associated with ischemic injury in the central nervous system. In addition, the present invention relates to compositions and methods useful for extending the therapeutic window associated with ischemic injury. | 2014-01-23 |
20140024598 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS - Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder. | 2014-01-23 |
20140024599 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE OR INJURY OF THE NERVOUS SYSTEM - Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell. | 2014-01-23 |
20140024600 | METHODS AND COMPOSITIONS FOR MODULATING DRUG-POLYMER ARCHITECTURE, PHARMACOKINETICS AND BIODISTRIBUTION - Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers. | 2014-01-23 |
20140024601 | CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS - The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain. | 2014-01-23 |
20140024602 | POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT AND PREVENTION OF DISORDERS ASSOCIATED WITH PROGENITOR CELL MOBILIZATION - Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided. | 2014-01-23 |
20140024603 | Method for Enhancing the Growth and Fullness of Hair - New fibroblast growth factor receptor 1 (FGFR1) inhibitors have been identified which are useful for promoting the retention and/or growth of keratin fibers, such as hair of the scalp, hair of the face (moustache, beard, etc.), eyebrows, eyelashes, and the like. The FGFR1 inhibitors may be formulated in effective amounts in a variety of cosmetic and personal care products. | 2014-01-23 |
20140024604 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES - Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. | 2014-01-23 |
20140024605 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer. | 2014-01-23 |
20140024606 | PEPTIDOMIMETICS COMPRISING N-AMINO CYCLIC UREA RESIDUES AND USES THEREOF - Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed. Use of such peptidomimetics for modulating the activity of CD36 or IL-1 receptor in a cell, and for treating CD36- or IL-1-related disease, disorder or condition is also described | 2014-01-23 |
20140024607 | NGNA COMPOSITIONS AND METHODS OF USE - The present invention relates to the field of viral disorders, and in particular to viral obesity. Compositions comprising nutraceutical agents are provided for treating viral obesity. Additionally, compositions comprising nutraceutical agents targeting adenoviruses are provided. | 2014-01-23 |
20140024608 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF - The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. | 2014-01-23 |
20140024609 | Treatment of Bacterial Infections - The present invention relates to methods of treating a bacterial infection in a subject in need thereof comprising administering to the subject an effective amount of the compound of Formula (I) and an anti-inflammatory agent. The present invention provides pharmaceutical compositions comprising an effective amount of the compound of Formula (I) and an anti-inflammatory agent. | 2014-01-23 |
20140024610 | NANOPARTICLES LOADED WITH CHEMOTHERAPEUTIC ANTITUMORAL DRUG - The invention relates to new therapeutic approaches for treating cancer, in particular hepatocellular carcinoma, with Nanoparticules loaded with a chemotherapeutic antitumoral agent. In particular, it relates to the treatment of cancer by administration of said Nanoparticules by intravenous infusion for at least 2 hours in order to prevent toxicological side effects and increase the benefit/risk ratio of the treatment. | 2014-01-23 |
20140024611 | ANTI-MICROBIAL AGENTS AND USES THEREOF - Many pathogens, including | 2014-01-23 |
20140024612 | FLUORINATED PYRIMIDINE ANALOGS AND METHODS OF USE THEREOF - Fluorinated pyrimidine analog compounds, compositions that include the fluorinated pyrimidine analog compounds, methods for making the fluorinated pyrimidine analog compounds, and methods for inhibiting DNA methyltransferase, treating solid tumors, and treating hematologic cancers by administering the fluorinated pyrimidine analog compounds. | 2014-01-23 |
20140024613 | Methods for Treating HCV - In one aspect, the present invention features HCV therapies comprising administering to a patient in need thereof an HCV protease inhibitor and ritonavir, wherein ritonavir is used as a pharmacokinetic booster to improve the pharmacokinetics of the HCV protease inhibitor. The HCV therapies do not require the testing of total cholesterol and triglyceride levels prior to and after the therapies. | 2014-01-23 |
20140024614 | TREATMENT OF BONE MARROW EDEMA (OEDEMA) WITH POLYSULFATED POLYSACCHARIDES - A method for the treatment of bone marrow edema in a mammal comprising administering an effective amount of a polysulfated polysaccharide including salts thereof, to a mammal in need of such treatment. | 2014-01-23 |
20140024615 | COMPOSITIONS AND METHODS FOR PREVENTING INFECTIOUS DISEASES IN FEMALES - A product that includes a bioadhesive treatment solution for prevention of infectious diseases in the urinary tract of a female is provided. The product includes a polysaccharide. The product is positioned over the urinary tract of a female to act as a barrier against infectious transfer. A method for applying the product and a method for making the product are also disclosed. | 2014-01-23 |
20140024616 | 5-FLUORO PYRIMIDINE DERIVATIVES - This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides. | 2014-01-23 |
20140024617 | TREATMENT OF CANCER WITH COMPLEX ORGANIC-INORGANIC PIGMENT COMPOSITIONS - The present invention includes compositions and methods for treating disorders of the skin or mucosa resulting from cancer therapies comprising: identifying a patient receiving cancer treatment; and administering to said patient an effective dose of a treated organic/inorganic complex material with an organic dye molecule or derivative thereof, in a pharmaceutically acceptable carrier. | 2014-01-23 |
20140024618 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS - The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient. | 2014-01-23 |
20140024619 | Benzazepine Derivatives Useful as Vasopressin Antagonists - The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) | 2014-01-23 |
20140024620 | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers - The invention features a method for treating patients who have an EGFR-driven cancer, which is, or has become, refractory to a tyrosine kinase inhibitor, such as eriotinib and gefitinib, by administering a compound of formula (I) to the patient. The invention also features treating EGFR-driven cancers having an EGFR mutation identified herein. | 2014-01-23 |
20140024621 | AMINOPYRIDINE COMPOUNDS AND THEIR USES - The invention generally relates to aminopyridines and methods of use thereof. In certain embodiments, the invention provides an aminopyridine or a pharmaceutically-acceptable salt thereof, in which the aminopyridine or the salt thereof includes a cleavable functional group that substantially prevents extra-hepatic hydrolysis. | 2014-01-23 |
20140024622 | COMPOSITIONS COMPRISING TRAMADOL AND CELECOXIB IN THE TREATMENT OF PAIN - The present invention relates to pharmaceutical compositions comprising tramadol and celecoxib and their uses as medicaments or analgesics, more particularly for the treatment of severe to moderate pain with an inflammation component. | 2014-01-23 |
20140024623 | POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT - The invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid. | 2014-01-23 |
20140024624 | Method of Ameliorating Clotting Pathologies and Related Materials and Methods - Methods for reducing blood clotting in a subject are provided, including methods to reduce the risk of and/or treat blot clotting pathologies. Also provided are compositions useful to reduce the risk or treat blood clotting pathologies. | 2014-01-23 |
20140024625 | Compositions and methods for using same for improving the quality of the meibum composition of meibomiam glands - This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6′s (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form. | 2014-01-23 |
20140024626 | USE OF CANTHAXANTHIN AND/OR 25-OH D3 FOR IMPROVED HATCHABILITY IN POULTRY - The present invention relates to the use canthaxanthin and/or 25-hydroxy vitamin D3 (25-OH D3) for improving breeder hatchability and fertility and for lowering embryo mortality in poultry. More particularly, the invention relates to the use of Canthaxanthin and/or 25-hydroxy canthaxanthin in the manufacture of a food or veterinary composition for improving hatchability in poultry. | 2014-01-23 |
20140024627 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES - The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease. | 2014-01-23 |
20140024628 | FUMARIC ACID SALT OF 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY-QUINAZOLIN-6-YLOXY]-1,4-DI- AZA-SPIRO[5.5]UNDECAN-5-ONE, ITS USE AS A MEDICAMENT AND THE PREPARATION THEREOF - The present invention relates to a compound of formula (I), | 2014-01-23 |
20140024629 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES - Provided herein are chemical matrices, compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are non-homogenous chemical matrices and compositions comprising an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent, wherein the alcohol is distributed within the chemical matrix as a microbubble. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders. | 2014-01-23 |
20140024630 | METHOD FOR THE NON-SURGICAL TREATMENT OF LIPODYSTROPHY IN A RETROVIRUS-INFECTED INDIVIDUAL - The present invention refers to a method for the non-surgical treatment of a lypodistrophy caused by an antiretroviral therapy in an individual infected by a retrovirus, such as HIV, and undergoing said antiretroviral therapy said method comprising the step of administering an effective amount of a adipocitolytic composition comprising deoxycholic acid and/or a pharmaceutically acceptable salt thereof in a retrovirus-infected individual affected by said lipodistrophy. | 2014-01-23 |
20140024631 | Steroids as Agonists for FXR - The invention relates to compounds of formula (I): | 2014-01-23 |
20140024632 | METHODS FOR TREATMENT OF AUTISM SPECTRUM DISORDER - The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorder. Accordingly, in one aspect, the present invention provides methods for treating patients with autism spectrum disorder. In one embodiment, a method for treating an autism spectrum disorder (ASD) in a patient comprises the step of administering a therapeutically effective amount of cholesterol to the patient. In more specific embodiments, the ASD is autism, Asperger's disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS), Rett's syndrome and childhood disintegrative disorder. In one embodiment, the patient has autism. | 2014-01-23 |
20140024633 | Orally administrable gallium compositions and methods of use - Provided are pharmaceutical gallium compositions that are particularly useful for oral administration. The pharmaceutical compositions include solid, liquid, and paste formulations, which have high oral gallium bioavailability and are suitable for human and veterinary applications. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate, gallium 8-quinolinolonate, or gallium nitrate, together with certain viscosity-increasing agents, such as water-soluble forms of methylcellulose or carboxymethylcellulose. | 2014-01-23 |
20140024634 | INDAZOLES - A method of treating a disease or condition for which a JAK inhibitor is indicated in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) | 2014-01-23 |
20140024635 | INHIBITORS OF THE INFLUENZA A VIRUS M2 PROTON CHANNEL - Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein. | 2014-01-23 |
20140024636 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT - Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), and is useful in the treatment of various diseases that are mediated by 11β-HSD1. | 2014-01-23 |
20140024637 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture - The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. | 2014-01-23 |
20140024638 | TREATMENT OF COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA - The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions, and methods for treating schizophrenia. | 2014-01-23 |
20140024639 | Compounds, Compositions, and Methods for Cancer Therapy - Compounds including various oligomers of piperlongumine and/or piperlongumine analogues as well as certain piperlongumine analogues that exhibit improved toxicity to cancer cells are disclosed. Also provided are compositions that comprise the compounds, methods of making compositions comprising the compounds, methods of making the compounds, and the use of compounds in methods for treating cancer. | 2014-01-23 |
20140024640 | Benzazepine Derivatives Useful as Vasopressin Antagonists - The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) | 2014-01-23 |
20140024641 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TRIPTANS - A method of treating exposure to organophosphate agents and preventing morbidity due to such exposure through the administration of a triptan compound to a subject. | 2014-01-23 |
20140024642 | OPHTHALMIC FORMULATION AND METHOD FOR AMELIORATING PRESBYOPIA - An ophthalmic formulation having an effective amount of a parasympathomimetic agent comprising pilocarpine, or a pharmaceutically acceptable salt thereof, and one or more α1 adrenergic agonists or antagonists is disclosed. The ophthalmic formulation may enable treatment of conditions adversely affecting the visual acuity of a patient, including presbyopia. A method of using the disclosed ophthalmic formulation to treat or ameliorate symptoms of presbyopia is also disclosed. | 2014-01-23 |
20140024643 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE - This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2014-01-23 |
20140024644 | 5-HT3 RECEPTOR ANTAGONISTS - The present invention provides 5-HT3 receptor antagonists of Formula (I): | 2014-01-23 |
20140024645 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS - Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same. | 2014-01-23 |
20140024646 | OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I). | 2014-01-23 |
20140024647 | AROMATIC HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY - A compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof is provided. The present invention is related to a compound represented by the formula (I), wherein R | 2014-01-23 |
20140024648 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS - The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R | 2014-01-23 |
20140024649 | Substituted Benzamides and Their Uses - Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use. | 2014-01-23 |
20140024650 | SULFONAMIDE DERIVATIVE AND USE THEREOF - Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): | 2014-01-23 |
20140024651 | UNIVERSAL SURFACE DECONTAMINATION FORMULATION - Provided are decontamination compositions that include an ammonium compound, a ferric/ferrocyanide compound, a polyaminocarboxylic acid compound and a polycarboxylic compound. Depending on the mode of application, the compositions can be used as foams, liquids, gels, strippable coatings, mists, or in other forms. Also provided are kits that include such components in whole or in part along with an optional dispersing device for use of the decontamination composition. | 2014-01-23 |
20140024652 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES - This invention relates to novel substituted triazolophthalazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering selective α5 receptor partial or full inverse agonists. | 2014-01-23 |
20140024653 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING PI3K INHIBITOR AND MEK INHIBITOR - Methods of treating patients with cancer are provided, wherein the methods comprise administering to the patient an effective amount of a MEK inhibitor and an effective amount of a PI3K inhibitor. Compositions in which the MEK and PI3K inhibitors are combined also are described. | 2014-01-23 |
20140024654 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS - Compounds of the following formula are provided for use with PARP: | 2014-01-23 |